Differential effects of short-term growth hormone therapy on the cardiovascular risk profile in patients with chronic kidney disease: A pilot study

Clinical Nephrology

Volumn 72, Issue 5, 2009, Pages 344-352

  Fischer, Dagmar Christiane ^a   Nissel, R ^a   Puhlmann, A ^a   Mitzner, A ^b   Tiess M ^c   Schmidt, R ^b   Haffner, D ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Dialysis Center North   (Germany)

Author keywords

Cardiovascular risk factors; Chronic kidney disease; FGF 23; Growth hormone treatment; Leptin; Phosphorous

Indexed keywords

25 HYDROXYVITAMIN D; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR 23; FLUINDOSTATIN; FOLIC ACID; GLUCOSE; HOMOCYSTEINE; HUMAN GROWTH HORMONE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PARATHYROID HORMONE; PHOSPHATE; SIMVASTATIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; UREA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; EVENING DOSAGE; FLUID RETENTION; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; NEPHRONOPHTHISIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 70350757431     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72344     Document Type: Article

References (34)

1. Abdulle AM, Gillett MP, Abouchacra S, Sabri SM, Rukhaimi MA, Obineche EN, Singh J. Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem. 2007; 302: 195-201.
2. Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C. Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. J Clin Endocrinol Metab. 1998; 83: 81-87.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
4. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U. Arterial and cardiac disease in young adults with childhood-on set end-stage renal disease - impact of calcium and vitamin D therapy. Nephrol Dial Trans plant. 2006; 21: 1906-1914.
5. Briley LP, Szczech LA. Leptin and renal disease. Semin Dial. 2006; 19: 54-59.
6. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant. 1994; 9: 1136-1142.
7. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. 2006; 17: S267-S273.
8. Capaldo B, Guardasole V, Pardo F, Matarazzo M, Di Rella F, Numis F, Merola B, Longobardi S, Sacca L. Abnormal vascular reactivity in growth hormone deficiency. Circulation. 2001; 103: 520-524.
9. Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007; 18: 2161-2171.
10. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16-S23.
11. Fontan MP, Rodriguez-Carmona A, Cordido F, Garcia-Buela J. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis. Am J Kidney Dis. 1999; 34: 824-831.
12. Fouque D, Juillard L, Lasne Y, Tabakian A, Laville M, Joly MO, Laville M. Acute leptin regulation in end-stage renal failure: the role of growth hormone and IGF-1. Kidney Int. 1998; 54: 932-937.
13. Garibotto G, Barreca A, Sofia A, Russo R, Fiorini F, Cappelli G, Cavatorta F, Cesarone A, Franceschini R Sacco P, Minuto F, Barreca T. Effects of growth hormone on leptin metabolism and energy expenditure in hemodialysis patients with protein-caloric malnutrition. J Am Soc Nephrol. 2000; 11: 2106-2113.
14. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, Mc Carron DA, Raggi P, Shanahan CM, Yorioka N. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004; 43: 572-579.
15. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592.
16. Haffner D, Nissel R, Wuhl E, Schaefer F, Bettendorf M, Tonshoff B, Mehls O. Metabolic effects of long-term growth hormone treatment in prepubertal children with chronic renal failure and after kidney transplantation. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Pediatr Res. 1998; 43: 209-215.
17. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med. 2000; 343: 923-930.
18. Heimbürger O, Stenvinkel P. Adipokines in chronic kidney disease - fat tissue gives nephrologists a message. Peritoneal dialysis international. J Int Soc Perit Dial. 2005; 25: 340-342.
19. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Aguilera A, Burgues S, Martinez-Ara J, Miguel JL, Gomez-Pan A, Selgas R. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kid ney Dis. 1998; 32: 454-463.
20. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Bajo MA, Aguilera A, Mendez J, Codoceo R, Selgas R. Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Trans plant. 2002; 17: 260-264.
21. Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab. 2005; 90: 3978-3982.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth DA. More accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
23. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613-620.
24. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008; 23: 41-48.
25. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1394-1401.
26. Møller N, Butler PC, Antsiferov MA, Alberti KG. Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia. 1989; 32: 105-110.
27. Nissel R, Fischer D-C, Puhlmann A, Mitzner A, Körber T, Tiess M, Holdt-Lehmann B, Schmidt R, Haffner D. Short-term growth hormone treatment and microcirculation: Effects in patients with chronic kidney disease. Microvasc. Res. 2009; 78: 246-252.
28. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999; 84: 453-457.
29. Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F. Growth hormone resistance in uremia a role for impaired JAK/STAT signaling. Pediatr Nephrol. 2005; 20: 313-318.
30. Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R. Impaired JAK-STAT signal transduction con tributes to growth hormone resistance in chronic uremia. J Clin Invest. 2001; 108: 467-475.
31. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees LA. Bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol. 2008; 19: 1239-1246.
32. Twickler TB, Wilmink HW, Schreuder PC, Cabezas MC, van Dam PS, Koppeschaar HP, Erkelens DW, Dallinga-Thie GM. Growth hormone (GH) treatment decreases postprandial remnant-like particle cholesterol concentration and improves endothelial function in adult-onset GH deficiency. J Clin Endocrinol Metab. 2000; 85: 4683-4689.
33. Wright NM, Papadea N, Wentz B, Hollis B, Willi S, Bell NH. Increased serum 1,25-dihydroxyvitamin D after growth hormone administration is not parathyroid hormone-mediated. Calcif Tissue Int. 1997; 61: 101-103.
34. Yilmaz, MI Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural E. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation. 2005; 80: 1660-1666.